DE69728585D1 - Mittel gegen Juckreiz - Google Patents

Mittel gegen Juckreiz

Info

Publication number
DE69728585D1
DE69728585D1 DE69728585T DE69728585T DE69728585D1 DE 69728585 D1 DE69728585 D1 DE 69728585D1 DE 69728585 T DE69728585 T DE 69728585T DE 69728585 T DE69728585 T DE 69728585T DE 69728585 D1 DE69728585 D1 DE 69728585D1
Authority
DE
Germany
Prior art keywords
antipruritic agent
antipruritic
morphinian
opiate
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69728585T
Other languages
English (en)
Other versions
DE69728585T2 (de
Inventor
Hiroshi Nagase
Jun Utsumi
Takashi Endoh
Toshiaki Tanaka
Kuniaki Kawamura
Junzo Kamei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18041771&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69728585(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Publication of DE69728585D1 publication Critical patent/DE69728585D1/de
Application granted granted Critical
Publication of DE69728585T2 publication Critical patent/DE69728585T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
DE69728585T 1996-11-25 1997-11-21 Mittel gegen Juckreiz Expired - Lifetime DE69728585T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP31347696 1996-11-25
JP31347696 1996-11-25

Publications (2)

Publication Number Publication Date
DE69728585D1 true DE69728585D1 (de) 2004-05-13
DE69728585T2 DE69728585T2 (de) 2004-08-05

Family

ID=18041771

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69732868T Expired - Lifetime DE69732868T2 (de) 1996-11-25 1997-11-21 Mittel gegen Juckreiz
DE69728585T Expired - Lifetime DE69728585T2 (de) 1996-11-25 1997-11-21 Mittel gegen Juckreiz
DE69737592T Expired - Lifetime DE69737592T2 (de) 1996-11-25 1997-11-21 Mittel gegen juckreiz

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69732868T Expired - Lifetime DE69732868T2 (de) 1996-11-25 1997-11-21 Mittel gegen Juckreiz

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69737592T Expired - Lifetime DE69737592T2 (de) 1996-11-25 1997-11-21 Mittel gegen juckreiz

Country Status (15)

Country Link
US (2) US6174891B1 (de)
EP (5) EP1327444B1 (de)
KR (1) KR100557801B1 (de)
CN (3) CN1291717C (de)
AT (3) ATE263563T1 (de)
AU (1) AU738743B2 (de)
CA (1) CA2244256C (de)
DE (3) DE69732868T2 (de)
DK (1) DK0897726T3 (de)
ES (3) ES2236630T3 (de)
NO (1) NO316309B1 (de)
NZ (1) NZ331001A (de)
PT (1) PT897726E (de)
TW (1) TW542838B (de)
WO (1) WO1998023290A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763445A (en) * 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
AU1290797A (en) * 1996-12-24 1998-07-17 George F. El Khoury Topical application of opioid drugs such as morphine for relief of itching and skin disease or irritation
JP2003526594A (ja) * 1997-07-14 2003-09-09 アドラー コーポレーション カッパ・アゴニスト抗掻痒薬学的製剤およびそれにより掻痒を治療する方法
JP3211027B2 (ja) * 1998-11-13 2001-09-25 丸石製薬株式会社 カプサイシン含有外用剤
WO2001014382A1 (fr) * 1999-08-23 2001-03-01 Toray Industries, Inc. Analgesiques contenant des derives sel d'ammonium quaternaire comme principe actif
JP4867123B2 (ja) * 1999-08-24 2012-02-01 東レ株式会社 神経因性疼痛治療剤および神経因性疼痛のモデル動物
WO2001074819A1 (fr) * 2000-04-03 2001-10-11 Toray Industries, Inc. Agents analgesiques contenant des derives de n-oxyde de morphinane en tant que principe actif
JP2002249442A (ja) * 2001-02-21 2002-09-06 Fumakilla Ltd アレルギー減感作治療薬
PT1380306E (pt) 2001-03-30 2009-05-25 Toray Industries Medicamentos para psiconeurose
US6617308B2 (en) 2001-04-30 2003-09-09 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons
US7294688B2 (en) 2001-04-30 2007-11-13 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons
US7652025B2 (en) * 2001-05-08 2010-01-26 Toray Industries, Inc. Remedies for sepsis
US6844438B2 (en) 2001-08-15 2005-01-18 Mclean Hospital Corporation N-substituted derivatives of morphinan and uses thereof
EP1450824A4 (de) * 2001-11-02 2005-09-28 Elan Corp Plc Pharmazeutische zusammensetzung
CN1642929B (zh) 2002-03-29 2010-05-12 参天制药株式会社 含有2-苯基苯并噻唑啉衍生物的κ-阿片样物质受体激动剂
JP5189242B2 (ja) * 2002-09-23 2013-04-24 アルケルメス ファーマ アイルランド リミテッド 乱用抵抗性の医薬組成物
WO2004029059A1 (en) * 2002-09-25 2004-04-08 Euro-Celtique S.A. N-substituted hydromorphones and the use thereof
CN100586434C (zh) 2004-03-30 2010-02-03 东丽株式会社 止痒剂
US7704522B2 (en) * 2004-09-08 2010-04-27 Clyde Morgan Topical medicament
AU2005286733B2 (en) * 2004-09-23 2009-11-05 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20060159748A1 (en) * 2004-12-23 2006-07-20 Rajesh Jain Oral immediate release formulation of a poorly water-soluble active substance
US7453122B2 (en) * 2005-02-08 2008-11-18 Taiwan Semiconductor Manufacturing Co., Ltd. SOI MOSFET device with reduced polysilicon loading on active area
CN101137658B (zh) * 2005-03-10 2011-06-08 东丽株式会社 用于与多发性硬化症伴随的搔痒的止痒剂
HUE029202T2 (en) 2005-04-06 2017-02-28 Toray Industries Crystals and procedure for the preparation of morphinane derivatives
ES2464593T3 (es) * 2005-11-09 2014-06-03 Toray Industries, Inc. Agente terapéutico o profiláctico para trastornos funcionales digestivos
AU2006328765B2 (en) * 2005-12-21 2012-01-12 Toray Industries, Inc. Antitussive agent
WO2008036172A1 (en) * 2006-09-20 2008-03-27 Mallinckrodt Inc. Preparation of substituted morphinan-6-ones and salts and intermediates thereof
PL2137189T3 (pl) * 2007-03-06 2015-12-31 SpecGx LLC Sposób wytwarzania czwartorzędowych N-alkilowych soli alkaloidu morfinanowego
US9040726B2 (en) * 2007-03-06 2015-05-26 Mallinckrodt Llc Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
US8796301B2 (en) 2007-04-24 2014-08-05 Toray Industries, Inc. Therapeutic or prophylactic agent for dyskinesia
AU2008244936B2 (en) 2007-04-26 2013-02-21 Toray Industries, Inc. Stable solid preparation comprising 4,5-epoxymorphinan derivative
EP2168580B1 (de) * 2007-06-22 2015-12-02 Toray Industries, Inc. Heilmittel oder prophylaktikum für schizophrenie
WO2009044883A1 (ja) 2007-10-05 2009-04-09 Toray Industries, Inc. モルヒナン誘導体またはその薬理学的に許容される酸付加塩を有効成分とする皮膚性状改善治療薬
WO2009138734A2 (en) * 2008-05-14 2009-11-19 Serentis Limited Use of opioid compounds in peripheral pain, wound healing and scar formation
EP2285780B1 (de) * 2008-05-27 2015-08-26 Mallinckrodt LLC Verfahren und verbindungen zur herstellung von normorphinanen
US9458109B2 (en) * 2008-09-03 2016-10-04 Mallinckrodt Llc Substituted berbines and processes for their synthesis
US8946419B2 (en) 2009-02-23 2015-02-03 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
WO2010096788A1 (en) * 2009-02-23 2010-08-26 Mallinckrodt Inc. (+)-morphinanium quaternary salts and processes for their production
WO2010096791A1 (en) * 2009-02-23 2010-08-26 Mallinckrodt Inc. (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
WO2010096790A1 (en) * 2009-02-23 2010-08-26 Mallinckrodt Inc. (+)-morphinananium n-oxides and processes for their production
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
WO2011093441A1 (ja) 2010-01-29 2011-08-04 東レ株式会社 胆道疾患の治療又は予防剤
CN103327977B (zh) 2011-01-31 2016-05-04 东丽株式会社 恶液质的治疗或预防剂
CA2845187A1 (en) 2011-09-08 2013-03-14 Peter X. Wang Production of alkaloids without the isolation of intermediates
JP6064252B2 (ja) * 2012-01-19 2017-01-25 三笠製薬株式会社 そう痒症改善経皮吸収貼付剤
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
AU2013359017B2 (en) * 2012-12-14 2018-05-10 Trevi Therapeutics, Inc. Methods for treating pruritus
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
WO2016052617A1 (ja) * 2014-09-30 2016-04-07 国立大学法人筑波大学 ナルフラフィン含有局所適用製剤
TW201707703A (zh) * 2015-06-04 2017-03-01 Tokai Capsule Co Ltd 軟膠囊劑
CN106866688B (zh) * 2015-12-10 2019-05-03 山东诚创医药技术开发有限公司 一种纳呋拉啡的精制方法
BR112018069174A2 (pt) * 2016-03-21 2019-01-29 Trevi Therapeutics Inc tratamento de prurido urêmico
WO2018103624A1 (zh) * 2016-12-06 2018-06-14 江苏恒瑞医药股份有限公司 一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途
WO2019171333A1 (en) 2018-03-08 2019-09-12 Victoria Link Ltd Treatment of demyelinating diseases
WO2020023486A1 (en) 2018-07-23 2020-01-30 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness and dyspnea
WO2020203609A1 (ja) * 2019-03-29 2020-10-08 日本ケミファ株式会社 掻痒を治療するためのｔ型カルシウムチャネル阻害剤の使用
WO2022004788A1 (ja) 2020-06-30 2022-01-06 東レ株式会社 代謝異常を伴う疾患又は症候群における筋力低下症状の改善剤又は予防剤
CA3220039A1 (en) 2021-06-14 2022-12-22 Jr. David St. Jean Urea derivatives which can be used to treat cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU196376B (en) * 1985-05-23 1988-11-28 Sandoz Ag Process for preparing morphinane derivatives and pharmaceutical compositions containing such compounds
US5021413B1 (en) * 1988-08-24 1994-12-13 Sankyo Co Analgesic thiomorpholins, their preparation, and pharmaceutical compositions containing them
CA2017020A1 (en) * 1989-05-18 1990-11-18 Alan Naylor Chemical compounds
DE69321525T2 (de) * 1992-01-23 1999-03-04 Toray Industries Morphinan-derivate und medizinische verwendung
JPH06122677A (ja) * 1992-08-28 1994-05-06 Sankyo Co Ltd 光学活性なカルボン酸アミド誘導体
DE69413933T2 (de) * 1993-06-30 1999-04-08 Toray Industries Antitussiva
AU690155B2 (en) * 1993-10-20 1998-04-23 Boots Company Plc, The Ibuprofen and flurbiprofen as anti-pruritic agents
IT1273751B (it) 1994-02-11 1997-07-10 Smithkline Beecham Farma Derivati azaciclici
JP2003526594A (ja) * 1997-07-14 2003-09-09 アドラー コーポレーション カッパ・アゴニスト抗掻痒薬学的製剤およびそれにより掻痒を治療する方法
US5760023A (en) 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith

Also Published As

Publication number Publication date
EP0897726B1 (de) 2007-04-11
ATE263563T1 (de) 2004-04-15
CA2244256C (en) 2006-07-11
DK0897726T3 (da) 2007-08-13
DE69737592T2 (de) 2008-01-03
EP1310251A1 (de) 2003-05-14
TW542838B (en) 2003-07-21
EP1327444B1 (de) 2005-03-23
DE69732868D1 (de) 2005-04-28
PT897726E (pt) 2007-07-09
DE69732868T2 (de) 2006-04-13
AU738743B2 (en) 2001-09-27
EP0897726A4 (de) 2003-05-28
ATE359076T1 (de) 2007-05-15
CA2244256A1 (en) 1998-06-04
EP0897726A1 (de) 1999-02-24
ES2236630T3 (es) 2005-07-16
CN1530111A (zh) 2004-09-22
DE69728585T2 (de) 2004-08-05
US6316461B1 (en) 2001-11-13
DE69737592D1 (de) 2007-05-24
CN1291717C (zh) 2006-12-27
NO983431L (no) 1998-09-24
NO983431D0 (no) 1998-07-24
EP1312361A1 (de) 2003-05-21
NO316309B1 (no) 2004-01-12
CN1535687A (zh) 2004-10-13
EP1327444A1 (de) 2003-07-16
KR100557801B1 (ko) 2006-04-21
NZ331001A (en) 2000-05-26
JP3531170B2 (ja) 2004-05-24
ES2285733T3 (es) 2007-11-16
ES2215158T3 (es) 2004-10-01
EP1310255B1 (de) 2004-04-07
AU4968397A (en) 1998-06-22
US6174891B1 (en) 2001-01-16
KR19990081978A (ko) 1999-11-15
EP1310255A1 (de) 2003-05-14
CN1214634A (zh) 1999-04-21
WO1998023290A1 (fr) 1998-06-04
ATE291429T1 (de) 2005-04-15
CN1180844C (zh) 2004-12-22

Similar Documents

Publication Publication Date Title
DE69728585D1 (de) Mittel gegen Juckreiz
AU2002213336A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
NO20004872L (no) FremgangsmÕte for Õ stabilisere farmasøytiske sammensetninger ved spesiell anvendelse av en antioksidant
PT800519E (pt) Compostos moduladores de receptores de esteroides e metodos
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
ID18883A (id) Pesaing 5-ht 1f
TW200420573A (en) Bifunctional heterocyclic compounds and methods of making and using same
RS63204A (en) Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
ATE231872T1 (de) Thiazolopyrimidinderivate
DE69928655D1 (de) Substituierte porphyrine
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
ATE386742T1 (de) Imidazonaphthyridine
PT971922E (pt) Compostos de tetra-hidropirido
PT1282418E (pt) Utilizacao de derivados pirazolo para o tratamento da infertilidade
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
BR0206917A (pt) Uso de antagonistas de mglur5 para o tratamento de condições prurìticas
NO20002408D0 (no) 5-HT1F antagonister
NO20005548D0 (no) Mykobakterieinhibitorer
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
EA199800858A1 (ru) Способ лечения насморка или аллергического ринита
BR0214244A (pt) Uso de uma ascomicina
EA200001105A1 (ru) 10-камфорсульфонат пароксетина для лечения нарушений цнс
ECSP972266A (es) Terapia de combinacion para el tratamiento de psicosis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition